Abstract: FR-PO420

Laboratory Indices and Serum Biomarkers Associate with Prior Renal Functional Decline in CKD

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 301 CKD: Risk Factors for Incidence and Progression

Authors

  • Martin, William P., National University of Ireland, Galway, Ireland
  • Ferguson, John P., HRB Clinical Research Facility, Galway, Ireland
  • Fitzgerald, Peter, Randox Laboratories Limited, 55 Diamond Road, Crumlin, County Antrim, BT29 4QY, United Kingdom
  • Griffin, Matthew D., National University of Ireland, Galway, Ireland
  • Naicker, Serika D., National University of Ireland, Galway, Ireland
  • Mccole, Eibhlin M., Randox Teoranta, Meenmore, Dungloe, County Donegal, F94 TV06, Ireland
  • Logue, Susan, National University of Ireland, Galway, Ireland
  • Cormican, Sarah, National University of Ireland, Galway, Ireland
  • Mcgarvey, Marie, Randox Teoranta, Meenmore, Dungloe, County Donegal, F94 TV06, Ireland
  • Richardson, Ciaran, Randox Teoranta, Meenmore, Dungloe, County Donegal, F94 TV06, Ireland
  • Mcconnell, Ivan, Randox Laboratories Limited, 55 Diamond Road, Crumlin, County Antrim, BT29 4QY, United Kingdom
  • Lamont, John, Randox Laboratories Limited, 55 Diamond Road, Crumlin, County Antrim, BT29 4QY, United Kingdom
Background

Prediction of renal functional decline in chronic kidney disease (CKD) is limited. We evaluated the relationship between laboratory indices and results from a novel serum biomarker chip assay with recent rate of decline of renal function.

Methods

Patients were recruited from Nephrology clinics at a tertiary referral center during 2014 and 2015, where they provided a serum sample for biomarker quantification with a novel multi-analyte chip assay. Relationships between laboratory indices and serum biomarkers at recruitment with slope of MDRD eGFR prior to recruitment were investigated using a custom weighted least squares algorithm adjusting for age, sex, and first eGFR during the study period.

Results

170 subjects were identified (135 (79.4%) with native CKD, 35 (20.6%) with kidney transplants (KTs)). Mean age was 60.09 ± 17.38 years. 69 (40.6%) subjects were female. Native CKD stages were: 5 (3.7%) CKD1, 17 (12.6%) CKD2, 19 (14.1%) CKD3a, 40 (29.6%) CKD3b, 44 (32.6%) CKD4, and 10 (7.4%) CKD5. Median [IQR] number of eGFR measurements was 17.0 [10.8, 27.3] over 3.3 [2.4, 3.7] years prior to recruitment. Rate of eGFR decline was -2.59 ± 5.29 vs. -0.46 ± 5.27 mL/min/BSA/year in native CKD and KT subjects, respectively (p = .035). Analysis results for selected laboratory and biomarker indices are summarized in the Table.

Conclusion

Multiple serum biomarkers measured simultaneously with a novel chip assay and several laboratory indices were strongly associated with prior renal functional decline in CKD subjects. Retrospective eGFR trends may be of value for identifying biomarker signatures associated with rapid renal functional decline.

Association of serum laboratory indices and biomarkers with slope of MDRD eGFR by multivariable regression.
 n (%)p
Serum Laboratory Indices 
Hemoglobin170 (100.0%)<.001
Phosphate169 (99.4%)<.001
Albumin170 (100.0%)<.001
Serum Biomarkers 
Fatty acid-binding protein 1130 (76.5%).009
Tumor necrosis factor soluble receptor 1125 (73.5%)<.001
Tumor necrosis factor soluble receptor 2129 (75.9%)<.001
Neutrophil gelatinase-associated lipocalin130 (76.5%).006
Cystatin C130 (76.5%)<.001

Funding

  • Commercial Support